Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

285 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-10-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized phase III trial to compare the effectiveness of immediate adjuvant chemotherapy with that of adjuvant chemotherapy given when the cancer returns in treating patients who have undergone a radical cystectomy for stage III or stage IV transitional cell carcinoma of the bladder urothelium. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known if adjuvant chemotherapy is more effective when given immediately after radical cystectomy (surgery to remove the bladder) or when the cancer returns.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

NCT00003640

Bladder Cancer

TERMINATED PHASE2

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

NCT00080795

Bladder Cancer Transitional Cell Cancer of the Renal Pelvis and Ureter Urethral Cancer

COMPLETED PHASE2

Combination Chemotherapy in Treating Patients With Bladder Cancer

NCT00003701

Bladder Cancer Urethral Cancer

COMPLETED PHASE3

Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer

NCT00042887

Bladder Cancer

TERMINATED PHASE3

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

NCT00003129

Bladder Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Compare the overall and progression-free survival of patients with stage III or IV transitional cell carcinoma of the bladder urothelium treated with immediate versus deferred adjuvant chemotherapy after radical cystectomy.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, tumor status (pT1-2 vs pT3 vs pT4), and node status (node positive vs node negative with 15 or more nodes sampled vs node negative with less than 15 nodes sampled). Patients are randomized to one of two treatment arms.

ARM I: Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.

ARM II: Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.

Patients in both arms receive one of the following chemotherapy regimens to be determined by participating center:

REGIMEN A (Classical M-VAC): Patients receive classical M-VAC comprising methotrexate IV on days 1, 15 and 22; vinblastine IV on days 2, 15, and 22; and doxorubicin IV and cisplatin IV on day 2. Courses repeat every 28 days.

REGIMEN B (High-dose M-VAC): Patients receive high-dose M-VAC comprising methotrexate IV on day 1 and vinblastine IV, doxorubicin IV, and cisplatin IV on day 2. Patients also receive filgrastim (G-CSF subcutaneously once daily on days 4-10. Courses repeat every 14 days.

REGIMEN C (Gemcitabine and cisplatin): Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 followed by cisplatin IV on day 1 or 2. Courses repeat every 28 days.

Patients are followed every 3 months for 1 year, every 6 months for 5 years, and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK and EORTC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stage III Bladder Cancer Stage IV Bladder Cancer Transitional Cell Carcinoma of the Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (immediate chemotherapy)

Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.

Group Type ACTIVE_COMPARATOR

doxorubicin hydrochloride

Intervention Type DRUG

Given IV

gemcitabine hydrochloride

Intervention Type DRUG

Given IV

vinblastine sulfate

Intervention Type DRUG

Given IV

methotrexate

Intervention Type DRUG

Given IV

cisplatin

Intervention Type DRUG

Given IV

filgrastim

Intervention Type BIOLOGICAL

Given SC

Arm II (deferred chemotherapy)

Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.

Group Type EXPERIMENTAL

doxorubicin hydrochloride

Intervention Type DRUG

Given IV

gemcitabine hydrochloride

Intervention Type DRUG

Given IV

vinblastine sulfate

Intervention Type DRUG

Given IV

methotrexate

Intervention Type DRUG

Given IV

cisplatin

Intervention Type DRUG

Given IV

filgrastim

Intervention Type BIOLOGICAL

Given SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

doxorubicin hydrochloride

Given IV

Intervention Type DRUG

gemcitabine hydrochloride

Given IV

Intervention Type DRUG

vinblastine sulfate

Given IV

Intervention Type DRUG

methotrexate

Given IV

Intervention Type DRUG

cisplatin

Given IV

Intervention Type DRUG

filgrastim

Given SC

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ADM ADR Adria Adriamycin PFS Adriamycin RDF dFdC difluorodeoxycytidine hydrochloride gemcitabine Gemzar 29060-LE Exal Velban Velbe Velsar amethopterin Folex methylaminopterin Mexate MTX CACP CDDP CPDD DDP G-CSF Neupogen

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed transitional cell carcinoma of the bladder urothelium

* T3-4, N1-3, M0
* No pure squamous cell or adenocarcinoma tumors
* No more than 90 days since prior radical cystectomy and bilateral lymphadenectomy without evidence of microscopic residual disease
* Performance status - WHO 0-1
* WBC at least 3,500/mm\^3
* Platelet count at least 120,000/mm\^3
* SGOT/SGPT less than 2.5 times upper limit of normal (ULN)
* Alkaline phosphatase less than 2.5 times ULN
* Bilirubin normal
* Glomerular filtration rate greater than 60 mL/min
* No clinically significant cardiac arrhythmia
* No congestive heart failure
* No complete bundle branch block
* No New York Heart Association class III or IV heart disease
* Not pregnant or nursing
* Fertile patients must use effective contraception during and for 6 months after study
* Considered fit for cisplatin-containing combination chemotherapy
* No clinically abnormal auditory function
* No known hypersensitivity to E. coli-derived drug preparations
* No grade 2 or greater peripheral neuropathy
* No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix, treated basal cell skin cancer, or treated incidental prostate cancer (pT2, Gleason score no greater than 6, and PSA less than 0.5 ng/mL)
* No psychological, familial, sociological, or geographical condition that would preclude study involvement
* No prior systemic chemotherapy
* No prior radiotherapy to the bladder

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cora Sternberg, Dr.

Role: STUDY_CHAIR

San Camillo Forlanini Hospitals

References

Explore related publications, articles, or registry entries linked to this study.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Theodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogenitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11.

Reference Type DERIVED

PMID: 25498218 (View on PubMed)